TrialESMO open2023
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.
C Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this paperpooled ittrialcites it